DE60336347D1 - Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung - Google Patents
Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierungInfo
- Publication number
- DE60336347D1 DE60336347D1 DE60336347T DE60336347T DE60336347D1 DE 60336347 D1 DE60336347 D1 DE 60336347D1 DE 60336347 T DE60336347 T DE 60336347T DE 60336347 T DE60336347 T DE 60336347T DE 60336347 D1 DE60336347 D1 DE 60336347D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- fibrocyte differentiation
- wound
- suppressing
- sap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004069 differentiation Effects 0.000 title abstract 2
- 210000000630 fibrocyte Anatomy 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000035876 healing Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43604602P | 2002-12-23 | 2002-12-23 | |
US43602702P | 2002-12-23 | 2002-12-23 | |
US51577603P | 2003-10-30 | 2003-10-30 | |
US51946703P | 2003-11-12 | 2003-11-12 | |
US52517503P | 2003-11-26 | 2003-11-26 | |
PCT/US2003/040957 WO2004058292A2 (en) | 2002-12-23 | 2003-12-22 | Methods and compositions for suppressing fibrocyte differentiation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60336347D1 true DE60336347D1 (de) | 2011-04-21 |
Family
ID=32686361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60326273T Expired - Lifetime DE60326273D1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
DE60336347T Expired - Lifetime DE60336347D1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60326273T Expired - Lifetime DE60326273D1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
Country Status (13)
Country | Link |
---|---|
US (3) | US7935682B2 (de) |
EP (3) | EP2017617A1 (de) |
JP (4) | JP4819364B2 (de) |
AT (2) | ATE422943T1 (de) |
AU (2) | AU2003300266B2 (de) |
CA (2) | CA2509241C (de) |
CY (1) | CY1111536T1 (de) |
DE (2) | DE60326273D1 (de) |
DK (1) | DK1596880T3 (de) |
ES (1) | ES2318195T3 (de) |
IL (1) | IL169258A0 (de) |
PT (1) | PT1596880E (de) |
WO (2) | WO2004059318A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
WO2007094776A1 (en) * | 2006-02-15 | 2007-08-23 | William Marsh Rice University | Compositions and methods for suppressing fibrocyte differentiation |
US20100297074A1 (en) * | 2002-12-23 | 2010-11-25 | Richard Hans Gomer | Wound healing compositions, systems, and methods |
US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
JP4819364B2 (ja) | 2002-12-23 | 2011-11-24 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物 |
US20060264367A1 (en) * | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
US8642307B2 (en) * | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
WO2008067559A2 (en) | 2006-11-30 | 2008-06-05 | University Of Virginia Patent Foundation | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
US8247370B2 (en) | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
US20100267933A1 (en) | 2006-12-21 | 2010-10-21 | Moya Wilson | Purification of proteins |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
WO2009155962A1 (en) * | 2008-06-27 | 2009-12-30 | Pentraxin Therapeutics Limited | Use |
GB0712503D0 (en) * | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
DK2370561T3 (da) * | 2008-12-16 | 2019-10-21 | Emd Millipore Corp | Omrøringstankreaktor og fremgangsmåde |
JP5797565B2 (ja) | 2009-03-11 | 2015-10-21 | プロメディオール, インコーポレイテッド | 過敏性障害(hypersensitive disorder)に対する処置および診断方法 |
CA2755047C (en) | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
US20100266643A1 (en) * | 2009-04-01 | 2010-10-21 | Willett W Scott | Pulmonary and nasal delivery of serum amyloid p |
UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
ES2552793T3 (es) | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
US9434716B2 (en) | 2011-03-01 | 2016-09-06 | Glaxo Group Limited | Antigen binding proteins |
EP3597671B1 (de) | 2010-05-17 | 2022-09-21 | EMD Millipore Corporation | Stimulusreaktive polymere zur aufreinigung von biomolekülen |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
EP2790690A4 (de) * | 2011-12-14 | 2015-08-12 | Texas A & M Univ Sys | Zusammensetzungen und verfahren zur verwaltung neutrophiler bewegungen unter verwendung des serum-amyloids p (sap) |
JP6340319B2 (ja) * | 2011-12-21 | 2018-06-06 | プロメディオール, インコーポレイテッド | 血清アミロイドp−抗体融合タンパク質 |
JP6104286B2 (ja) * | 2013-01-21 | 2017-03-29 | 三菱電機株式会社 | 電気機器識別システム、電気機器、及び、電気機器識別方法 |
WO2014160336A1 (en) * | 2013-03-13 | 2014-10-02 | University Of Kentucky Research Foundation | METHODS OF ADMINISTERING IgG1 ANTIBODIES AND METHODS OF SUPPRESSING ANGIOGENESIS |
JP6601707B2 (ja) * | 2015-02-15 | 2019-11-06 | 国立大学法人金沢大学 | 線維化判定方法 |
US20190046547A1 (en) * | 2016-02-08 | 2019-02-14 | Hackensack University Medical Center | Compositions and methods for treating chronic wounds |
JP6780600B2 (ja) * | 2017-07-28 | 2020-11-04 | 株式会社デンソー | 内燃機関制御システム |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
DE2725261C2 (de) | 1977-06-03 | 1986-10-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung |
GB1594389A (en) | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
EP0321703B1 (de) * | 1987-11-20 | 1993-04-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Sorbentmittel für Serum-Amyloid-Proteine |
US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
AU712819B2 (en) * | 1996-01-25 | 1999-11-18 | Profylakse Aps | Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
IL137919A0 (en) * | 1998-02-17 | 2001-10-31 | Medarex Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
DE99907899T1 (de) * | 1998-03-11 | 2005-01-13 | Kabushiki Kaisha Soken | Hautnormalisierungsmittel |
JPH11319542A (ja) | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
EP1267795A1 (de) * | 2000-03-30 | 2003-01-02 | Brennen Medical Inc. | Antimikrobielle und immunstimulierende zusammensetzung |
US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2002098278A2 (en) * | 2001-06-04 | 2002-12-12 | Cytokine Pharmasciences, Inc | Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
JP4819364B2 (ja) * | 2002-12-23 | 2011-11-24 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物 |
MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 FcγRIIB 특이적 항체 및 그의 사용 방법 |
WO2006002438A2 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor i (cd64) |
-
2003
- 2003-12-22 JP JP2004564024A patent/JP4819364B2/ja not_active Expired - Fee Related
- 2003-12-22 US US11/158,723 patent/US7935682B2/en active Active
- 2003-12-22 CA CA2509241A patent/CA2509241C/en not_active Expired - Lifetime
- 2003-12-22 EP EP08165673A patent/EP2017617A1/de not_active Withdrawn
- 2003-12-22 AU AU2003300266A patent/AU2003300266B2/en not_active Expired
- 2003-12-22 DE DE60326273T patent/DE60326273D1/de not_active Expired - Lifetime
- 2003-12-22 DE DE60336347T patent/DE60336347D1/de not_active Expired - Lifetime
- 2003-12-22 AT AT03800146T patent/ATE422943T1/de not_active IP Right Cessation
- 2003-12-22 PT PT03814319T patent/PT1596880E/pt unknown
- 2003-12-22 WO PCT/US2003/041183 patent/WO2004059318A2/en active Application Filing
- 2003-12-22 EP EP03814319A patent/EP1596880B1/de not_active Expired - Lifetime
- 2003-12-22 WO PCT/US2003/040957 patent/WO2004058292A2/en active Application Filing
- 2003-12-22 EP EP03800146A patent/EP1576368B1/de not_active Expired - Lifetime
- 2003-12-22 ES ES03800146T patent/ES2318195T3/es not_active Expired - Lifetime
- 2003-12-22 AT AT03814319T patent/ATE500839T1/de active
- 2003-12-22 AU AU2003299873A patent/AU2003299873A1/en not_active Abandoned
- 2003-12-22 DK DK03814319.4T patent/DK1596880T3/da active
- 2003-12-22 CA CA002509392A patent/CA2509392A1/en not_active Abandoned
- 2003-12-22 JP JP2004563958A patent/JP4922560B2/ja not_active Expired - Lifetime
-
2005
- 2005-06-17 IL IL169258A patent/IL169258A0/en unknown
- 2005-06-22 US US11/158,966 patent/US7666432B2/en active Active
-
2010
- 2010-09-02 JP JP2010196332A patent/JP2011016824A/ja active Pending
-
2011
- 2011-06-08 CY CY20111100544T patent/CY1111536T1/el unknown
- 2011-09-02 US US13/224,959 patent/US8187599B2/en not_active Expired - Fee Related
-
2014
- 2014-03-24 JP JP2014059598A patent/JP2014141512A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60336347D1 (de) | Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung | |
ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
ATE409037T1 (de) | Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen | |
DE602004023829D1 (de) | Verfahren zur behandlung von sinuskopfschmerzen | |
TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
ATE550005T1 (de) | Integriertes wundverbandsystem | |
BRPI0509363A (pt) | método para aumentar a eficácia preservativa de uma composição, composição oftálmica, método de tratamento de uma condição oftálmica e processo para produzir uma composição oftálmica | |
DE60229406D1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
AU2002361878A1 (en) | Method of improving wound healing | |
ATE495735T1 (de) | Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden | |
ATE459349T1 (de) | Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen | |
DE69902154T2 (de) | Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung. | |
ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
DE60212613D1 (de) | Doxycyclin zur behandlung von akne | |
DE60114439D1 (de) | Verfahren zur antimikrobiellen behandlung von fasermaterialien | |
DE60220043D1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
AU2003301761A8 (en) | Method for treating wounds to promote healing | |
ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
DE602007010459D1 (de) | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie | |
EE200300580A (et) | Meetod ja inertse absorbeeriva savi kasutamine segu töötlemiseks ning saadus | |
ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
ATE374025T1 (de) | Verbindungen zur beseitigung und/oder linderung der anhedonie | |
ATE314066T1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
ATE270895T1 (de) | Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen | |
DE60210645D1 (de) | Zusammensetzung und verfahren zur behandlung von oberflächen |